Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia

Blood

Volumn 121, Issue 21, 2013, Pages 4287-4294

  Klepin, Heidi D ^a   Geiger, Ann M ^a   Tooze, Janet A ^a   Kritchevsky, Stephen B ^a   Williamson, Jeff D ^a   Pardee, Timothy S ^a   Ellis, Leslie R ^a   Powell, Bayard L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; ANTHRACYCLINE; BORTEZOMIB; CREATININE; CYTARABINE; ETOPOSIDE; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; BONE MARROW BIOPSY; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; COGNITION; COMORBIDITY; DAILY LIFE ACTIVITY; DEPRESSION; DISTRESS SYNDROME; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GRIP STRENGTH; HAND GRIP; HOSPITALIZATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICAL PERFORMANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT; VERY ELDERLY; ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; EMOTIONAL DISORDER; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MOTOR ACTIVITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME;

AFFECTIVE SYMPTOMS; AGED; COGNITION; COMORBIDITY; DEPRESSION; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MOTOR ACTIVITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880422627     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-471680     Document Type: Article

References (69)

1. National Cancer Institute. Surveillance Epidemiology and End Results. http://seer.cancer. gov/csr/1975-2006/index.html. Accessed April 4, 2013.
2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107(9):3481-3485.
3. Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006; 106(5):1090-1098.
4. Löwenberg B, Zittoun R, Kerkhofs H, et al; On the value of intensive remission-induction chemotherapy in elderly patients of 651 years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7(9):1268-1274.
5. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in New Engl J Med. 2010;362(12):1155]. N Engl J Med. 2009;361(13):1235-1248.
6. Rowe JM, Neuberg D, Friedenberg W, et al; Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-485.
7. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18): 4179-4187.
8. Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22): 4422-4429.
9. Juliusson G; Swedish AML Group. Most 70-to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment. Blood. 2011; 117(12):3473-3474.
10. Balducci L, Cohen HJ, Engstrom PF, et al; National Comprehensive Cancer Network. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3(4): 572-590.
11. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100(4):1224-1232.
12. Farag SS, Archer KJ, Mrózek K, et al; Cancer and Leukemia Group B 8461. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108(1): 63-73.
13. Fröhling S, Schlenk RF, Kayser S, et al; German-Austrian AML Study Group. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006; 108(10):3280-3288.
14. van der Holt B, Löwenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood. 2005; 106(8):2646-2654.
15. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824-1831.
16. Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16(11): 1795-1800.
17. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9): 1998-2005.
18. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494-502.
19. Caillet P, Canoui-Poitrine F, Vouriot J, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol. 2011; 29(27):3636-3642.
20. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012; 118(13):3377-3386.
21. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457-3465.
22. Kanesvaran R, Li H, Koo KN, Poon D. Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol. 2011;29(27):3620-3627.
23. Klepin HD, Geiger AM, Tooze JA, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011;59(10):1837-1846.
24. Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98(3):548-553.
25. Bland RC, Newman SC. Mild dementia or cognitive impairment: the Modified Mini-Mental State examination (3MS) as a screen for dementia. Can J Psychiatry. 2001;46(6):506-510.
26. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987; 48(8):314-318.
27. Beekman AT, Deeg DJ, Van Limbeek J, Braam AW, De Vries MZ, Van Tilburg W. Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in The Netherlands. Psychol Med. 1997;27(1): 231-235.
28. Nelson CJ, Cho C, Berk AR, Holland J, Roth AJ. Are gold standard depression measures appropriate for use in geriatric cancer patients? A systematic evaluation of self-report depression instruments used with geriatric, cancer, and geriatric cancer samples. J Clin Oncol. 2010; 28(2):348-356.
29. Mitchell AJ. Short screening tools for cancerrelated distress: a review and diagnostic validity meta-analysis. J Natl Compr Canc Netw. 2010; 8(4):487-494.
30. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82(10): 1904-1908.
31. Hurria A, Li D, Hansen K, et al. Distress in older patients with cancer. J Clin Oncol. 2009;27(26): 4346-4351.
32. Ettinger WH Jr, Burns R, Messier SP, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA. 1997;277(1):25-31.
33. Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum. 2004;50(5):1501-1510.
34. Rejeski WJ, Ip EH, Marsh AP, Miller ME, Farmer DF. Measuring disability in older adults: the International Classification System of Functioning, Disability and Health (ICF) framework. Geriatr Gerontol Int. 2008;8(1):48-54.
35. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc. 1983;31(12): 721-727.
36. Rantanen T, Volpato S, Ferrucci L, Heikkinen E, Fried LP, Guralnik JM. Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism. J Am Geriatr Soc. 2003;51(5):636-641.
37. Bandinelli S, Lauretani F, Boscherini V, et al. A randomized, controlled trial of disability prevention in frail older patients screened in primary care: the FRASI study. Design and baseline evaluation. Aging Clin Exp Res. 2006; 18(5):359-366.
38. Corsonello A, Lattanzio F, Pedone C, et al. Prognostic significance of the short physical performance battery in older patients discharged from acute care hospitals. Rejuvenation Res. 2012;15(1):41-48.
39. Freire AN, Guerra RO, Alvarado B, Guralnik JM, Zunzunegui MV. Validity and reliability of the short physical performance battery in two diverse older adult populations in Quebec and Brazil. J Aging Health. 2012;24(5):863-878.
40. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994; 49(2):M85-M94.
41. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332(9): 556-561.
42. Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55(4):M221-M231.
43. Ostir GV, Volpato S, Fried LP, Chaves P, Guralnik JM; Women's Health and Aging Study. Reliability and sensitivity to change assessed for a summary measure of lower body function: results from the Women's Health and Aging Study. J Clin Epidemiol. 2002;55(9):916-921.
44. Studenski S, Perera S, Wallace D, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc. 2003;51(3):314-322.
45. Volpato S, Cavalieri M, Sioulis F, et al. Predictive value of the Short Physical Performance Battery following hospitalization in older patients. J Gerontol A Biol Sci Med Sci. 2011;66(1):89-96.
46. National Institute on Aging. Assessing physical performance in the older patient. http://www.grc. nia.nih.gov/branches/ledb/sppb. Accessed April 4, 2013.
47. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8): 2912-2919.
48. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136(4):624-627.
49. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published correction appears in J Clin Oncol. 2004;22(3):576.]. J Clin Oncol. 2003;21(24):4642-4649.
50. Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics. 1995;51(4):1469-1482.
51. Lin DY, Wei LJ, Ying GZ. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80(3):557-572.
52. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med. 2011;30(1):22-38.
53. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51(2):524-532.
54. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109(2):265-273.
55. Röllig C, Thiede C, Gramatzki M, et al; Study Alliance Leukemia. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116(6): 971-978.
56. Aaldriks AA, Maartense E, le Cessie S, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol. 2011; 79(2):205-212.
57. Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30(15):1829-1834.
58. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1): 50-58.
59. Klepin HD, Geiger AM, Tooze JA, et al; Health, Aging and Body Composition Study. Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study. J Am Geriatr Soc. 2010;58(1):76-82.
60. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142-148.
61. Wedding U, Röhrig B, Klippstein A, Fricke HJ, Sayer HG, Höffken K. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol. 2006; 132(10):665-671.
62. Klepin HD, Danhauer SC, Tooze JA, et al. Exercise for older adult inpatients with acute myelogenous leukemia: a pilot study J Geriatr Oncol. 2011;2(1):11-17.
63. Bo M, Massaia M, Raspo S, et al. Predictive factors of in-hospital mortality in older patients admitted to a medical intensive care unit. J Am Geriatr Soc. 2003;51(4):529-533.
64. Boustani M, Baker MS, Campbell N, et al. Impact and recognition of cognitive impairment among hospitalized elders. J Hosp Med. 2010;5(2):69-75.
65. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4): 788-793.
66. Inouye SK. Delirium in older persons. N Engl J Med. 2006;354(11):1157-1165.
67. Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999; 340(9):669-676.
68. Breccia M, Frustaci AM, Cannella L, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol. 2009;27(3):148-153.
69. Savic A, Kvrgic V, Rajic N, Urosevic I, Kovacevic D, Percic I, Popovic S. The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res. 2012;36(4): 479-482.